

LivaNova plc : Annual Financial Report

April 29, 2016 1:23 PM ET

29 April 2016

LIVANOVA PLC

(the “Company”)

The Company announces that its UK Annual Report and IFRS Financial Statements for the period ended 31 December 2015 (“**2015 Annual Report**”) has been published today. The 2015 Annual Report has been made publicly available on the Company’s website (www.livanova.com/investor-relations/annual-meetings-and-reports).

The Company also announces that it will today file Amendment No.1 on Form 10-K/A, which amends the Transition Report on Form 10-K/T for the transitional period 25 April 2015 to 31 December 2015 filed by the Company with the US Securities and Exchange Commission (“**SEC**”) on 4 March 2015 (the “**Form 10-K/A**”). The Form 10-K/A will be viewable on the SEC’s website at www.sec.gov.

The 2015 Annual Report has been, and the Form 10-K/A will be, uploaded to the National Storage Mechanism and will be available for viewing shortly at <http://www.morningstar.co.uk/uk/NSM>.

The Company’s annual general meeting for 2016 (the “**AGM**”) will be held on 15 June 2016 at 1:00 p.m (British Summer Time) at the offices of Latham & Watkins (London) LLP, 99 Bishopsgate, London, EC2M 3XF, United Kingdom. Amongst other things, at the AGM, the directors will be seeking shareholder authority to repurchase the Company’s ordinary shares “on-market” on the London Stock Exchange and “off-market” on the NASDAQ Global Market pursuant to the Companies Act 2006. The 2015 Annual Report, together with the notice of AGM and accompanying proxy statement, will be posted to shareholders in due course.

About LivaNova

LivaNova PLC, headquartered in London, U.K., is a global medical technology company formed by the merger of Sorin S.p.A, a leader in the treatment of cardiovascular diseases, and Cyberonics Inc., a medical device company with core expertise in neuromodulation. LivaNova transforms medical innovation into meaningful solutions for the benefit of patients, healthcare professionals, and healthcare systems. The company employs approximately 4,500 employees worldwide. With a presence in more than 100 countries, LivaNova operates as three business units: Cardiac Rhythm Management, Cardiac Surgery, and Neuromodulation, with operating headquarters in Clamart (France), Mirandola (Italy) and Houston (U.S.), respectively.

LivaNova is listed on NASDAQ and listed on the Official List of the UK’s Financial Conduct Authority and traded on London Stock Exchange (LSE) under the ticker symbol “LIVN”.

For more information, please visit www.livanova.com, or contact:

Investor Relations and Media:

Karen King

Vice President, Investor Relations & Corporate Communications

Phone: +1 (281) 228-7262

Fax: +1 (281) 218-9332

e-mail: corporate.communications@livanova.com